BRIEF-Idera Pharma reports positive Phase 1 data for IMO-2125
February 24, 2017 at 13:42 PM EST
* Idera Pharmaceuticals presents update from ongoing phase 1 dose escalation clinical trial of Intratumoral IMO-2125 in combination with Ipilimumab in metastatic melanoma patients refractory to Anti-PD-1 treatment at the 2017 ASCO-SITC clinical Immuno-Oncology Symposium